Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report

Value in Health

Volumn 12, Issue 4, 2009, Pages 409-418

  Drummond, Michael ^a   Barbieri, Marco ^b   Cook, John ^c   Glick, Henry A ^d   Lis, Joanna ^e   Malik, Farzana ^f   Reed, Shelby D ^g   Rutten, Frans ^h   Sculpher, Mark ^a   Severens, Johan ⁱ  

^a UNIVERSITY OF YORK   (United Kingdom)

^b 13 Innovus ^*  (United Kingdom)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Sanofi Aventis Group Poland   (Poland)

^f Serono International SA   (Switzerland)

^g DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cost effectiveness analysis; Decision analytic models; Economic clinical trials; Resource allocation

Indexed keywords

CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DATA TRANSMISSION; DECISION ANALYTIC MODELING; DECISION MAKING; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; ISPOR GOOD RESEARCH PRACTICES; ORGANIZATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; RESOURCE ALLOCATION; REVIEW; STATISTICAL MODEL;

COST-BENEFIT ANALYSIS; DATA COLLECTION; DECISION SUPPORT TECHNIQUES; EUROPE; GREAT BRITAIN; HUMANS; MODELS, ECONOMIC; UNITED STATES;

EID: 66249124989     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00489.x     Document Type: Article

References (36)

1. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines: similarities, differences and some implications. Value Health 2001 4 : 225 50.
2. Tarn TY, Smith MD. Pharmacoeconomic guidelines around the world. ISPOR Connections 2004 10 : 5 12.
3. Sculpher MJ, Pang FS, Manca A, et al. Generalisability in economic evaluation studies in health care: a review and case studies. Health Technol Assess 2004 8 : 1 192.
4. Barbieri M, Drummond MF, Willke R, et al. Variability in cost-effectiveness estimates for pharmaceuticals in Western Europe: Lessons for inferring generalizability. Value Health 2005 8 : 10 23. (Pubitemid 40293637)
5. Barbieri M, Drummond MF, Rutten F, et al. What do international pharmacoeconomic guidelines say about economic data transferability In preparation, 2009).
6. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London : NICE, 2004.
7. College Voor Zorgverzekeringen. Dutch Guidelines for Pharmacoeconomic Research. Amstelveen, The Netherlands : Health Insurance Council, 1999.
8. Institute for Quality and Efficiency in Health Care (IQWiG). Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System. Cologne : IQWiG, 2008.
9. Manca A, Willan AR. Lost in translation: accounting for between-country differences in the analysis of multinational cost-effectiveness data. Pharmacoeconomics 2006 24 : 1101 19.
10. Welte R, Feenstra F, Jager H, Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004 22 : 857 76.
11. Cook JR, Drummond M, Glick H, Heyse JF. Assessing the appropriateness of combining economic data from multinational clinical trials. Stat Med 2003 22 : 1955 76.
12. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985 41 : 361 72.
13. Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ 1998 7 : 481 93.
14. Koopmanschap MA, Touw KC, Rutten FF. Analysis of costs and cost-effectiveness in multinational trials. Health Policy 2001 58 : 175 86.
15. Rice N, Jones A. Multilevel models and health economics. Health Econ 1997 6 : 561 75.
16. Manca A, Rice N, Sculpher MJ, Briggs AH. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Econ 2005 14 : 471 85.
17. Grieve R, Nixon R, Thompson SG, Normand C. Using multilevel models for assessing the variability of multinational resource use and cost data. Health Econ 2005 14 : 185 96.
18. Grieve R, Nixon R, Thompson SG, Cairns J. Multilevel models for estimating incremental net benefits in multinational studies. Health Econ 2007 16 : 815 26.
19. Pinto EM, Willan AR, O'Brien BJ. Cost-effectiveness analysis for multinational clinical trials. Stat Med 2005 24 : 1965 82.
20. Willan AR, Pinto EM, O'Brien BJ, et al. Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. Health Econ 2005 14 : 327 38.
21. Manca A, Lambert PC, Sculpher M, Rice N. Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modeling. Med Decis Making 2007 27 : 471 90.
22. Thompson SG, Nixon RM, Grieve R. Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study. J Health Econ 2006 25 : 1015 28.
23. Duncan C, Jones K, Moon G. Health-related behaviour in context: a multilevel modeling approach. Soc Sci Med 1996 42 : 817 30.
24. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care evaluation. Chichester : John Wiley & Sons, 2004.
25. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis. New York : Chapman & Hall/CRC, 2004.
26. Nixon RM, Thompson SG. Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. Health Econ 2005 14 : 1217 29.
27. Sculpher MJ, Claxton KP, Drummond MF, McCabe C. Whither trial-based economic evaluation for health care decision making? Health Econ 2006 15 : 677 87.
28. Sculpher M, Claxton K, Akehurst R. It's just evaluation for decision making: recent developments in, and challenges for, cost-effectiveness research. In : Smith PC, Ginnelly L, Sculpher M, eds. Health Policy and Economics. Opportunities and Challenges. Maidenhead, United Kingdom : Open University Press, 2005.
29. O'Shea JC, DeMets DL. Statistical issues relating to international differences in clinical trials. Am Heart J 2001 142 : 21 8.
30. Szende A, Oppe M, Devlin N. EQ-5D Value Sets: Inventory, Comparative Review and User Guide. Dordrecht : Springer, 2007.
31. Badia X, Roset M, Herdman M, et al. A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Med Decis Making 2001 21 : 7 16. (Pubitemid 32245026)
32. Busschbach J, Weijnen T, Nieuwenhuizen M, et al. A comparison of EQ-5D time trade-off values obtained in Germany, the United Kingdom and Spain. In : Brooks R, Rabin R, deCharro F, eds. The Measurement and Valuation of Health Status Using EQ-5D: a European Perspective. Dordrecht, The Netherlands : Kluwer Academic Publishers, 2003.
33. Levy AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 2008 11 : 527 38.
34. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. Oxford : Oxford University Press, 2005.
35. Palmer S, Sculpher M, Phillips Z, et al. Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIa antagonists in the UK National Health Service? Int J Cardiol 2005 100 : 229 40.
36. Sculpher MJ, Drummond MF. Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions? Pharamacoeconomics, 2006 24 : 1087 99.